167 related articles for article (PubMed ID: 34625644)
81. Early Detection of Leptomeningeal Metastases Among Patients Undergoing Spinal Stereotactic Radiosurgery.
Freret ME; Wijetunga NA; Shamseddine AA; Higginson DS; Schmitt AM; Yamada Y; Lis E; Boire A; Yang JT; Xu AJ
Adv Radiat Oncol; 2023; 8(2):101154. PubMed ID: 36845624
[TBL] [Abstract][Full Text] [Related]
82. Aumolertinib in NSCLC with leptomeningeal involvement, harbouring concurrent
Qin Z; Zhang H; Yan P; Yu L; Hong C; Calvetti L; Passaro A; Araujo A; Chen Y
J Thorac Dis; 2023 Jul; 15(7):4016-4026. PubMed ID: 37559636
[TBL] [Abstract][Full Text] [Related]
83. Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer.
Deng JY; Gou Q; Yang L; Chen ZH; Yang MY; Yang XR; Yan HH; Wei XW; Liu JQ; Su J; Zhong WZ; Xu CR; Wu YL; Zhou Q
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37463790
[TBL] [Abstract][Full Text] [Related]
84. Cell-free DNA from cerebrospinal fluid can be used to detect the
Liu Y; Yang S; Zhao J; He Z; Ma J; Guo Y; Wang W; Yoshizawa A; Prelaj A; Tiseo M; Normanno N; Van Schil PE; Wang Q; Yang X
Transl Lung Cancer Res; 2021 Feb; 10(2):914-925. PubMed ID: 33718032
[TBL] [Abstract][Full Text] [Related]
85. Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis.
Ahn MJ; Chiu CH; Cheng Y; Han JY; Goldberg SB; Greystoke A; Crawford J; Zhao Y; Huang X; Johnson M; Vishwanathan K; Yates JWT; Brown AP; Mendoza-Naranjo A; Mok T
J Thorac Oncol; 2020 Apr; 15(4):637-648. PubMed ID: 31887431
[TBL] [Abstract][Full Text] [Related]
86. The clinical utility of cfRNA for disease detection and surveillance: A proof of concept study in non-small cell lung cancer.
Metzenmacher M; Hegedüs B; Forster J; Schramm A; Horn PA; Klein CA; Bielefeld N; Ploenes T; Aigner C; Siveke JT; Schuler M; Lueong SS
Thorac Cancer; 2022 Aug; 13(15):2180-2191. PubMed ID: 35708207
[TBL] [Abstract][Full Text] [Related]
87. Highly sensitive fusion detection using plasma cell-free RNA in non-small-cell lung cancers.
Hasegawa N; Kohsaka S; Kurokawa K; Shinno Y; Takeda Nakamura I; Ueno T; Kojima S; Kawazu M; Suehara Y; Ishijima M; Goto Y; Kojima Y; Yonemori K; Hayashi T; Saito T; Shukuya T; Takahashi F; Takahashi K; Mano H
Cancer Sci; 2021 Oct; 112(10):4393-4403. PubMed ID: 34310819
[TBL] [Abstract][Full Text] [Related]
88. Circulating tumor cell and cell-free RNA capture and expression analysis identify platelet-associated genes in metastatic lung cancer.
Beck TN; Boumber YA; Aggarwal C; Pei J; Thrash-Bingham C; Fittipaldi P; Vlasenkova R; Rao C; Borghaei H; Cristofanilli M; Mehra R; Serebriiskii I; Alpaugh RK
BMC Cancer; 2019 Jun; 19(1):603. PubMed ID: 31215484
[TBL] [Abstract][Full Text] [Related]
89. Erlotinib for Non-Small Cell Lung Cancer with Leptomeningeal Metastases: A Phase II Study (LOGIK1101).
Nosaki K; Yamanaka T; Hamada A; Shiraishi Y; Harada T; Himeji D; Kitazaki T; Ebi N; Shimose T; Seto T; Takenoyama M; Sugio K
Oncologist; 2020 Dec; 25(12):e1869-e1878. PubMed ID: 32654250
[TBL] [Abstract][Full Text] [Related]
90. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments.
Zheng MM; Tu HY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Jiang BY; Yang XN; Yang XR; Deng JY; Yang MY; Xu BF; Chen XM; Li YS; Wu YL
Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375
[TBL] [Abstract][Full Text] [Related]
91. Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR-mutation non-small cell lung cancer: A phase II single-arm prospective clinical trial.
Lu ZQ; Cai J; Wang X; Wei JP; Zeng ZM; Huang L; Liu AW
Thorac Cancer; 2021 Jan; 12(2):172-180. PubMed ID: 33205587
[TBL] [Abstract][Full Text] [Related]
92. Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors.
Hendriks LEL; Bootsma G; Mourlanette J; Henon C; Mezquita L; Ferrara R; Audigier-Valette C; Mazieres J; Lefebvre C; Duchemann B; Cousin S; le Pechoux C; Botticella A; De Ruysscher D; Dingemans AC; Besse B
Eur J Cancer; 2019 Jul; 116():182-189. PubMed ID: 31203193
[TBL] [Abstract][Full Text] [Related]
93. SHP-1 promoter 2 methylation in cerebrospinal fluid for diagnosis of leptomeningeal epithelial-derived malignancy (carcinomatous meningitis).
Vinayanuwattikun C; Mingmalairak S; Jittapiromsak N; Thaipisuttikul I; Sriuranpong V; Mutirangura A; Shuangshoti S
J Neurooncol; 2016 Sep; 129(3):395-403. PubMed ID: 27401153
[TBL] [Abstract][Full Text] [Related]
94. Treatment Response To Osimertinib In
Li H; Yu T; Huang M; Guo A; Qian X; Yin Z
Onco Targets Ther; 2019; 12():7785-7790. PubMed ID: 31571928
[TBL] [Abstract][Full Text] [Related]
95. Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028).
Li M; Chen J; Zhang B; Yu J; Wang N; Li D; Shao Y; Zhu D; Liang C; Ma Y; Ou Q; Hou X; Chen L
BMC Med; 2022 Nov; 20(1):398. PubMed ID: 36372873
[TBL] [Abstract][Full Text] [Related]
96. Overexpression of syndecan-1, MUC-1, and putative stem cell markers in breast cancer leptomeningeal metastasis: a cerebrospinal fluid flow cytometry study.
Cordone I; Masi S; Summa V; Carosi M; Vidiri A; Fabi A; Pasquale A; Conti L; Rosito I; Carapella CM; Villani V; Pace A
Breast Cancer Res; 2017 Apr; 19(1):46. PubMed ID: 28399903
[TBL] [Abstract][Full Text] [Related]
97. A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
Park S; Lee MH; Seong M; Kim ST; Kang JH; Cho BC; Lee KH; Cho EK; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Ann Oncol; 2020 Oct; 31(10):1397-1404. PubMed ID: 32634610
[TBL] [Abstract][Full Text] [Related]
98. Multiple combination therapy based on intrathecal pemetrexed in non-small cell lung cancer patients with refractory leptomeningeal metastasis.
Miao Q; Zheng X; Zhang L; Jiang K; Wu B; Lin G
Ann Palliat Med; 2020 Nov; 9(6):4233-4245. PubMed ID: 33302683
[TBL] [Abstract][Full Text] [Related]
99. [Survival analysis of different kinds of tyrosine kinase inhibitors in the treatment of patients with epidermal growth factor receptor mutated non-small cell lung cancer and leptomeningeal metastasis].
Xu HY; Chen HQ; Kong JX; Zhang Y; Liu S; Yang GJ; Wang Y
Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):399-405. PubMed ID: 35144338
[No Abstract] [Full Text] [Related]
100. A Microfluidic, Multi-Antibody Cell Capture Method to Evaluate Tumor Cells in Cerebrospinal Fluid in Patients With Suspected Leptomeningeal Metastases.
Sweed NT; Hsiao HC; Blouw B; Pircher TJ; Fisher D; Naluz KR; Mayer JA; Dugan MC; Sharma A; Carrillo J; Kesari S
Arch Pathol Lab Med; 2024 May; ():. PubMed ID: 38797516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
